SG11201804969PA - Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof - Google Patents

Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof

Info

Publication number: SG11201804969PA
Authority: SG; Singapore
Prior art keywords: international; chimeric; street; pct; human ctla4
Prior art date: 2015-12-15

Application number

SG11201804969PA

Other languages

English (en)

Inventor

Yang Liu

Pan Zheng

Martin Devenport

Original Assignee

Oncoimmune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-15

Filing date

2016-12-14

Publication date

2018-07-30

2016-12-14 Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc

2018-07-30 Publication of SG11201804969PA publication Critical patent/SG11201804969PA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG11201804969PA 2015-12-15 2016-12-14 Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof SG11201804969PA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562267735P	2015-12-15	2015-12-15
US201662309169P	2016-03-16	2016-03-16
US201662359036P	2016-07-06	2016-07-06
PCT/US2016/066698 WO2017106372A1 (en)	2015-12-15	2016-12-14	Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
SG11201804969PA true SG11201804969PA (en)	2018-07-30

Family

ID=59057509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201804969PA SG11201804969PA (en)	2015-12-15	2016-12-14	Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof

Country Status (25)

Country	Link
US (3)	US10618960B2 (ru)
EP (2)	EP3389699B1 (ru)
JP (4)	JP6858779B2 (ru)
KR (1)	KR20180086219A (ru)
CN (2)	CN108430499B (ru)
AU (2)	AU2016370648B2 (ru)
BR (1)	BR112018012113A2 (ru)
CA (1)	CA3006984C (ru)
DK (1)	DK3389699T5 (ru)
ES (1)	ES2979210T3 (ru)
FI (1)	FI3389699T3 (ru)
HR (1)	HRP20240719T1 (ru)
HU (1)	HUE066907T2 (ru)
IL (3)	IL310404A (ru)
LT (1)	LT3389699T (ru)
MX (1)	MX2018006925A (ru)
MY (1)	MY186974A (ru)
PL (1)	PL3389699T3 (ru)
PT (1)	PT3389699T (ru)
RS (1)	RS65703B1 (ru)
SG (1)	SG11201804969PA (ru)
SI (1)	SI3389699T1 (ru)
TW (1)	TWI739781B (ru)
WO (1)	WO2017106372A1 (ru)
ZA (1)	ZA201804077B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2986765A1 (en)	2015-05-29	2016-12-08	Agenus Inc.	Anti-ctla-4 antibodies and methods of use thereof
EP3515489A4 (en) *	2016-09-19	2020-05-06	Oncoimmune, Inc.	CD80 AND CD86 BINDING PROTEIN COMPOSITIONS AND USES THEREOF
US11013802B2 (en)	2016-12-07	2021-05-25	Agenus Inc.	Anti-CTLA-4 antibodies and methods of use thereof
WO2019036855A1 (en)	2017-08-21	2019-02-28	Adagene Inc.	ANTI-CD137 MOLECULES AND THEIR USE
KR20200085828A (ko) *	2017-11-08	2020-07-15	젠코어 인코포레이티드	신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
WO2019148445A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Precision/context-dependent activatable antibodies, and methods of making and using the same
CN112135632A (zh) *	2018-02-02	2020-12-25	肿瘤免疫股份有限公司	选择和设计用于癌症疗法的更安全且更有效的抗ctla-4抗体的方法
WO2019148444A1 (en) *	2018-02-02	2019-08-08	Adagene Inc.	Anti-ctla4 antibodies and methods of making and using the same
WO2019152423A1 (en) *	2018-02-02	2019-08-08	Oncoimmune, Inc.	Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
CN112399973B (zh) *	2018-06-05	2022-12-16	江苏康宁杰瑞生物制药有限公司	二聚体及其用途
EP3617230A1 (en) *	2018-09-03	2020-03-04	BioInvent International AB	Novel antibodies and nucleotide sequences, and uses thereof
US20230071889A1 (en)	2018-12-21	2023-03-09	Ose Immunotherapeutics	Bifunctional anti-pd-1/il-7 molecule
KR20210121045A (ko) *	2018-12-27	2021-10-07	기가젠, 인코포레이티드	항-ctla-4 결합 단백질 및 이의 사용 방법
WO2020165374A1 (en)	2019-02-14	2020-08-20	Ose Immunotherapeutics	Bifunctional molecule comprising il-15ra
AU2020406083A1 (en)	2019-12-17	2022-06-16	Boehringer Ingelheim International Gmbh	Bifunctional molecules comprising an IL-7 variant
EP4136120A4 (en) *	2020-04-13	2024-07-03	Biosion Inc	CTLA4 BINDING ANTIBODIES AND THEIR USES
WO2022112198A1 (en)	2020-11-24	2022-06-02	Worldwide Innovative Network	Method to select the optimal immune checkpoint therapies
US20240018248A1 (en)	2020-12-02	2024-01-18	Vib Vzw	An ltbr agonist in combination therapy against cancer
KR20220112208A (ko) *	2021-02-03	2022-08-10	주식회사 유틸렉스	항 ctla-4 항체 및 이의 용도
WO2022214652A1 (en)	2021-04-09	2022-10-13	Ose Immunotherapeutics	Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
US20240182571A1 (en)	2021-04-09	2024-06-06	Ose Immunotherapeutics	New scaffold for bifunctional molecules with improved properties
JP7345889B2 (ja) *	2021-06-17	2023-09-19	株式会社ニューギン	遊技機
AU2022361768A1 (en) *	2021-10-08	2024-05-02	Kashiv Biosciences, Llc	Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022359021A1 (en) *	2021-10-08	2024-05-02	Kashiv Biosciences, Llc	Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2024003360A1 (en)	2022-07-01	2024-01-04	Institut Curie	Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en)	2022-08-02	2024-02-08	Ose Immunotherapeutics	Multifunctional molecule directed against cd28
WO2024059833A1 (en)	2022-09-16	2024-03-21	OncoC4, Inc.	Use of anti-ctla-4 antibodies for treating adenoid cystic carcinoma
WO2024194605A1 (en)	2023-03-17	2024-09-26	Quell Therapeutics Limited	Treg therapy
WO2024200823A1 (en)	2023-03-30	2024-10-03	Ose Immunotherapeutics	Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en)	2023-03-30	2024-10-03	Ose Immunotherapeutics	Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2024227176A1 (en)	2023-04-28	2024-10-31	OncoC4, Inc.	Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US6936704B1 (en)	1999-08-23	2005-08-30	Dana-Farber Cancer Institute, Inc.	Nucleic acids encoding costimulatory molecule B7-4
EP1210428B1 (en)	1999-08-23	2015-03-18	Dana-Farber Cancer Institute, Inc.	Pd-1, a receptor for b7-4, and uses therefor
US7605238B2 (en)	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
WO2001039722A2 (en)	1999-11-30	2001-06-07	Mayo Foundation For Medical Education And Research	B7-h1, a novel immunoregulatory molecule
US6803192B1 (en)	1999-11-30	2004-10-12	Mayo Foundation For Medical Education And Research	B7-H1, a novel immunoregulatory molecule
AU2002258941A1 (en)	2001-04-20	2002-11-05	Mayo Foundation For Medical Education And Research	Methods of enhancing cell responsiveness
WO2003042402A2 (en)	2001-11-13	2003-05-22	Dana-Farber Cancer Institute, Inc.	Agents that modulate immune cell activation and methods of use thereof
CN101899114A (zh)	2002-12-23	2010-12-01	惠氏公司	抗pd-1抗体及其用途
EP1793857A4 (en) *	2004-09-08	2008-09-03	Univ Ohio State Res Found	COMBINED THERAPY WITH ANTI-CTLA4 AND ANTI-4-1BB ANTIBODIES
US20090252741A1 (en) *	2004-09-08	2009-10-08	Ohio State University Research Foundation	Human monoclonal anti-ctla4 antibodies in cancer treatment
EP1828946B1 (en)	2004-10-15	2018-02-28	Symantec International	One time password
JP5127043B2 (ja)	2005-01-24	2013-01-23	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	ホスファチジルセリンに結合するｆｃ融合構築物およびそれらの治療用途
US8008449B2 (en) *	2005-05-09	2011-08-30	Medarex, Inc.	Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA3201163A1 (en)	2005-07-01	2007-01-11	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US8062852B2 (en)	2007-10-01	2011-11-22	The Children's Hospital And Regional Medical Center	Detection and treatment of autoimmune disorders
CN101628940B (zh) *	2008-07-15	2011-11-23	中国科学院生物物理研究所	一种单克隆抗体及其应用
GB0903325D0 (en) *	2009-02-26	2009-04-08	Univ Aberdeen	Antibody molecules
GB201103955D0 (en) *	2011-03-09	2011-04-20	Antitope Ltd	Antibodies
US20150079100A1 (en) *	2012-03-23	2015-03-19	Bristol-Myers Squibb Company	Methods of treatments using ctla-4 antibodies
LT2925350T (lt) *	2012-12-03	2019-04-10	Bristol-Myers Squibb Company	Imunomoduliuojančių fc sulietų baltymų priešvėžinio aktyvumo stiprinimas
WO2014209804A1 (en) *	2013-06-24	2014-12-31	Biomed Valley Discoveries, Inc.	Bispecific antibodies
CN104292334B (zh) *	2014-04-25	2018-11-27	河南省健康伟业生物医药研究股份有限公司	一种全人源抗ctla-4单克隆抗体、制备方法及应用

2016
- 2016-12-14 MX MX2018006925A patent/MX2018006925A/es unknown
- 2016-12-14 IL IL310404A patent/IL310404A/en unknown
- 2016-12-14 SI SI201631826T patent/SI3389699T1/sl unknown
- 2016-12-14 CN CN201680073425.2A patent/CN108430499B/zh active Active
- 2016-12-14 ES ES16876612T patent/ES2979210T3/es active Active
- 2016-12-14 DK DK16876612.9T patent/DK3389699T5/da active
- 2016-12-14 PL PL16876612.9T patent/PL3389699T3/pl unknown
- 2016-12-14 AU AU2016370648A patent/AU2016370648B2/en active Active
- 2016-12-14 LT LTEPPCT/US2016/066698T patent/LT3389699T/lt unknown
- 2016-12-14 HR HRP20240719TT patent/HRP20240719T1/hr unknown
- 2016-12-14 CA CA3006984A patent/CA3006984C/en active Active
- 2016-12-14 EP EP16876612.9A patent/EP3389699B1/en active Active
- 2016-12-14 MY MYPI2018000904A patent/MY186974A/en unknown
- 2016-12-14 SG SG11201804969PA patent/SG11201804969PA/en unknown
- 2016-12-14 EP EP24164173.7A patent/EP4374926A3/en active Pending
- 2016-12-14 PT PT168766129T patent/PT3389699T/pt unknown
- 2016-12-14 RS RS20240735A patent/RS65703B1/sr unknown
- 2016-12-14 US US16/062,350 patent/US10618960B2/en active Active
- 2016-12-14 IL IL259988A patent/IL259988B2/en unknown
- 2016-12-14 IL IL296354A patent/IL296354B2/en unknown
- 2016-12-14 HU HUE16876612A patent/HUE066907T2/hu unknown
- 2016-12-14 CN CN202210802423.XA patent/CN116063492A/zh active Pending
- 2016-12-14 JP JP2018530560A patent/JP6858779B2/ja active Active
- 2016-12-14 FI FIEP16876612.9T patent/FI3389699T3/fi active
- 2016-12-14 WO PCT/US2016/066698 patent/WO2017106372A1/en active Application Filing
- 2016-12-14 KR KR1020187017368A patent/KR20180086219A/ko not_active Application Discontinuation
- 2016-12-14 BR BR112018012113A patent/BR112018012113A2/pt active Search and Examination
- 2016-12-15 TW TW105141656A patent/TWI739781B/zh active
2018
- 2018-06-18 ZA ZA2018/04077A patent/ZA201804077B/en unknown
2020
- 2020-02-27 US US16/803,972 patent/US11629188B2/en active Active
2021
- 2021-03-23 JP JP2021049294A patent/JP2021100957A/ja active Pending
2022
- 2022-06-15 JP JP2022096901A patent/JP7286845B2/ja active Active
2023
- 2023-03-22 US US18/188,098 patent/US20230391870A1/en active Pending
- 2023-05-19 AU AU2023203169A patent/AU2023203169A1/en active Pending
- 2023-05-24 JP JP2023085801A patent/JP2023106547A/ja active Pending

Also Published As

Publication number	Publication date
IL259988A (en)	2018-07-31
HRP20240719T1 (hr)	2024-09-13
IL296354B1 (en)	2024-03-01
BR112018012113A2 (pt)	2018-12-04
ZA201804077B (en)	2019-09-25
HUE066907T2 (hu)	2024-09-28
DK3389699T5 (da)	2024-09-23
SI3389699T1 (sl)	2024-07-31
JP2019510733A (ja)	2019-04-18
IL310404A (en)	2024-03-01
US20230391870A1 (en)	2023-12-07
US10618960B2 (en)	2020-04-14
EP3389699B1 (en)	2024-05-01
CA3006984C (en)	2023-10-17
JP6858779B2 (ja)	2021-04-14
RS65703B1 (sr)	2024-07-31
EP4374926A2 (en)	2024-05-29
US11629188B2 (en)	2023-04-18
PL3389699T3 (pl)	2024-07-22
AU2023203169A1 (en)	2023-06-15
ES2979210T3 (es)	2024-09-24
JP2021100957A (ja)	2021-07-08
MX2018006925A (es)	2018-08-01
TWI739781B (zh)	2021-09-21
US20200283526A1 (en)	2020-09-10
JP2023106547A (ja)	2023-08-01
EP3389699A1 (en)	2018-10-24
WO2017106372A1 (en)	2017-06-22
CN108430499B (zh)	2022-07-19
TW201731877A (zh)	2017-09-16
PT3389699T (pt)	2024-06-04
KR20180086219A (ko)	2018-07-30
AU2016370648A1 (en)	2018-06-21
IL296354A (en)	2022-11-01
IL259988B2 (en)	2023-02-01
CN108430499A (zh)	2018-08-21
IL296354B2 (en)	2024-07-01
FI3389699T3 (fi)	2024-05-28
IL259988B (en)	2022-10-01
DK3389699T3 (da)	2024-05-13
JP7286845B2 (ja)	2023-06-05
US20190127468A1 (en)	2019-05-02
CA3006984A1 (en)	2017-06-22
JP2022123049A (ja)	2022-08-23
EP3389699A4 (en)	2019-07-10
LT3389699T (lt)	2024-06-10
EP4374926A3 (en)	2024-08-07
AU2016370648B2 (en)	2023-03-09
MY186974A (en)	2021-08-26
CN116063492A (zh)	2023-05-05

Publication	Publication Date	Title
SG11201804969PA (en)	2018-07-30	Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
SG11201805449PA (en)	2018-07-30	Methods of making chimeric antigen receptor -expressing cells
SG11201808724SA (en)	2018-11-29	Anti-tim-3 antibodies and compositions
SG11201806150RA (en)	2018-08-30	Psma and cd3 bispecific t cell engaging antibody constructs
SG11201804694SA (en)	2018-07-30	Dual controls for therapeutic cell activation or elimination
SG11201807474SA (en)	2018-11-29	Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201803956UA (en)	2018-06-28	Anti-dr5 antibodies and methods of use thereof
SG11201908088RA (en)	2019-10-30	Antibodies against pd-l1
SG11201810640RA (en)	2018-12-28	Cd33 specific chimeric antigen receptors
SG11201811003PA (en)	2019-01-30	Anti-pd-l1 antibodies and uses thereof
SG11201910134SA (en)	2019-11-28	Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201910027YA (en)	2019-11-28	Bispecific antibody against ox40 and ctla-4
SG11201908719QA (en)	2019-10-30	Biomarkers and car t cell therapies with enhanced efficacy
SG11201907753TA (en)	2019-09-27	Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201806496SA (en)	2018-08-30	Antigen binding proteins that bind pd-l1
SG11201903693QA (en)	2019-05-30	Polypeptide variants and uses thereof
SG11201909541WA (en)	2019-11-28	Chimeric antibody/t-cell receptor constructs and uses thereof
SG11201803703UA (en)	2018-06-28	Anti-complement factor c1q fab fragments and uses thereof
SG11201810697QA (en)	2018-12-28	Chimeric antigen receptor and car-t cells that bind bcma
SG11201810933QA (en)	2019-01-30	Anti-c5 antibodies and uses thereof
SG11201810591VA (en)	2018-12-28	Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
SG11201811431VA (en)	2019-01-30	Multispecific antibodies against cd40 and cd137
SG11201804839WA (en)	2018-07-30	Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201901020RA (en)	2019-03-28	Anti-siglec-7 antibodies for the treatment of cancer
SG11201805709RA (en)	2018-07-30	Anti-pro/latent myostatin antibodies and methods of use thereof